India Diabetes Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

India Diabetes Devices Market Trends and Insights

Rising Prevalence of Obesity Among Youth Accelerating Earlier-Onset Diabetes

India’s adolescent obesity wave is pulling diabetes incidence into the under-35 cohort, creating multi-decade device demand. A 2024 Journal of the Endocrine Society study reported 17.9% diabetes prevalence among Indians below 35 years.^{[1]Journal of the Endocrine Society, “Prevalence of Diabetes and Pre-Diabetes in Adolescents in India,” oxfordacademic.com} Device makers are repositioning: Dexcom launched ONE+ in 2024 at INR 4,000 per month, promoting smartphone-linked insights for young Type 2 users. Employer wellness plans follow suit, with MediBuddy data showing 24.40% pre-diabetes prevalence in employees aged 18-45, prompting group policies that bundle CGM rentals. Convergence of dyslipidemia and hypertension in obese youth strengthens the business case for integrated CGM platforms over stand-alone glucometers. The India diabetes devices market increasingly orients product roadmaps around this technology-savvy demographic.

Expanding Public Reimbursement for CGM Sensors

The Central Government Health Scheme raised the ceiling to INR 300,000 for sensor-augmented pumps and INR 4,000 for 14-day CGM use in its 2024 rate list.^{[2]Central Government Health Scheme, “CGHS Rate List 2024,” cghs.gov.in} Although only 4 million beneficiaries currently qualify, the policy shift signals strategic support for continuous monitoring. Tamil Nadu’s state plan added annual CGM coverage for Type-1 patients, capping benefits at INR 50,000. Limited physician familiarity stalls uptake: the Indian Diabetes Federation found fewer than 30% of primary-care doctors were trained to interpret ambulatory glucose profiles. Still, the reimbursement tailwind is material to the India diabetes devices market trajectory as other states emulate early adopters.

Rising Prevalence and Earlier Onset of Type-2 Diabetes

The Indian Council of Medical Research counted 101 million diagnosed diabetics and 136 million people in pre-diabetes in 2024, with incidence cresting in the 30-45 bracket.^{[3]Indian Council of Medical Research, “ICMR-INDIAB Study,” icmr.gov.in} Earlier insulin initiation drives demand for disposable pens and prefilled cartridges. Novo Nordisk introduced Ozempic in December 2025 at INR 2,200 per week, demonstrating pharmaceutical recognition that convenience trumps cost for upwardly mobile Type 2 cohorts. Real-world telemedicine data from Jothydev’s Diabetes & Research Centre showed that long-term complication rates fell to 9.8% under digital monitoring, underscoring the clinical value of connected SMBG and CGM programs.

Government PLI Scheme Spurring Local Diabetes-Device Manufacturing

The INR 3,420 crore PLI program has green-lighted 19 greenfield projects and generated cumulative device sales worth INR 8,039 crore by 2024. Schott’s 2025 commissioning of borosilicate cartridge tubing in Gujarat slashed insulin-device lead times from 12 weeks to 4 weeks. Roche’s Chennai assembly line cut landed meter costs by 15%, letting it underprice Chinese imports in tier-2 pharmacies. These milestones reduce import dependency, stabilize supply, and lift the India diabetes devices market toward higher local value added.

High Out-of-Pocket Costs on Testing Consumables

SMBG strips cost INR 380-1,993 per pack, implying an annual spend of INR 13,860-19,930 for twice-daily testing. Abbott’s FreeStyle Libre 3 sensor at INR 5,000 every 14 days lifts annual CGM spend to INR 130,000. These figures exceed the median household income in many tier-3 cities, forcing patients to ration tests and slowing the transition to CGM. Private insurers cap diabetes consumable reimbursement at around INR 10,000 per year, covering less than 10% of CGM expenses. Affordability remains the sharpest brake on the India diabetes devices market.

Low CGM-Prescription Awareness Among Primary-Care Physicians

Primary-care doctors manage 70% of India’s diabetic patients, yet the Indian Diabetes Federation survey shows fewer than 30% have formal CGM training. Consultation slots average five minutes, inadequate for sensor education. Abbott’s Libre 2 Plus eliminates calibration to ease workflows, but concerns about data overload persist. Endocrinologists, mostly metro-based, prescribe CGM at quintuple the general-practice rate, leaving rural users underserved. Until tele-mentorship and CME credits are tied to CGM competence, physician inertia will continue to dampen the expansion of the India diabetes devices market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Management Devices Outpace Monitoring on Insulin-Delivery Innovation

Management devices are forecast to post a 3.53% CAGR through 2031, outstripping monitoring counterparts. Demand rides on rapid insulin-pump uptake among 1.2 million Type-1 patients and swelling disposable-pen use in urban Type-2 cohorts. Medtronic’s MiniMed 780G hybrid closed-loop system, launched in 2024, automatically adjusts basal insulin every five minutes and has widened time-in-range by 15% in Indian trials. AgVa Healthcare’s INSUL pump, locally priced at INR 24,999, undercuts imported pumps by 90% and integrates Bluetooth dosing logs, capturing value-conscious consumers. Schott’s domestic cartridge tubing reduced landed costs on insulin pens by 20%, encouraging Novo Nordisk to phase out vial formats in favor of FlexPen devices.

Monitoring devices still delivered a 61.78% revenue share in 2025, buoyed by 80 million glucometer users; however, their 1.9% CAGR lags behind the market pace. SMBG strips remain the default for price-sensitive buyers, but CGM is the fastest-growing sub-segment. Abbott’s Libre 3 sensor measures just 2.9 mm in diameter and beams one-minute readings via Bluetooth, while Dexcom’s ONE+ offers a 10-day sensor life at INR 4,000 per month. Combined, these launches have nudged the India diabetes devices market toward continuous data capture, although premium pricing keeps penetration below 7% of diagnosed diabetics.

By Patient Type: Type-1 Segment Accelerates on Pediatric-Onset Surge

Type-2 cases dominate volume at 91.43% in 2025, yet the Type-1 slice of the India diabetes devices market size is growing nearly twice as fast, posting a 4.89% CAGR to 2031. Earlier pediatric diagnoses and universal insulin dependency drive intensive device use. The MiniMed 780G capitalizes on this need with Guardian 4 sensor integration that cuts hypoglycemia events by 30%. School-based awareness programs in Bengaluru and Delhi have doubled the number of pediatric pump initiations since 2024, aided by CGHS coverage ceilings that now reimburse up to INR 300,000 for sensor-augmented pumps.

Type 2 patients are migrating from episodic finger sticks toward real-time tracking as employer wellness mandates expand. GLP-1 launches add momentum; Ozempic’s once-weekly dosing at INR 2,200 lowers daily injection burden and complements CGM dashboards for dose titration. As tele-diabetes clinics extend reach, Type-2 users will integrate SMBG and CGM data, sustaining the broader India diabetes devices market growth.

By End User: Home-Care Settings Surge on Telehealth Integration

Hospitals and specialty clinics retained 53.48% of 2025 revenue because initial CGM prescriptions and pump initiations require supervised titration. Nonetheless, home-care settings are projected to deliver the fastest growth at a 5.17% CAGR, lifting their share of the 318.6 million consultations provided by eSanjeevani, which offers a scalable physician interface for remote dose adjustments. The Ayushman Bharat Digital Mission has issued 568 million health IDs, enabling patients to share their CGM streams with doctors and insurers in real-time. Roche’s channel partnerships with Phable and PharmEasy bundle Accu-Chek meters with three-month digital coaching, demonstrating how pharmacy-integrated programs can reinforce adherence.

Primary-care and diabetes centers, though smaller by value, influence device adoption curves. BeatO’s pharmacy-linked SMBG service, covering 1.5 million users, triggers teleconsults based on strip refill data, resulting in a 10% glucose reduction within 90 days. Employer-funded platforms echo this trajectory; MediBuddy’s cohort analysis spurred corporations to include CGM rentals in benefits. Multinationals reinforce the digital pivot: Medtronic is investing USD 50 million in a Pune software hub to develop cloud analytics for closed-loop systems. As CDSCO guides tele-prescription of insulin analogs, routine dose titration will continue its migration from clinic to living room, strengthening home-care’s pull on the India diabetes devices market.

Geography Analysis

Regional dynamics frame the India diabetes devices industry’s expansion path. Metros such as Mumbai, Delhi-NCR, Bengaluru, and Hyderabad reflect higher disposable income and specialist density. CGM adoption in these hubs is three times the national average, helped by private-sector insurance that reimburses sensors and disposable pens. 

Tier-2 cities, including Jaipur, Lucknow, Coimbatore, and Indore, are experiencing the fastest growth in incremental volume. Government PLI clusters in Gujarat and Tamil Nadu shorten supply chains, letting local distributors trim SMBG strip prices by 8-10%. Intensifying e-pharmacy penetration also improves last-mile access, narrowing the urban-rural gap. Still, cold-chain limitations curb the uptake of insulin cartridges, moderating the growth of management devices relative to monitoring kits in these regions.

Tier-3 cities and rural markets hold the largest patient pool. Limited endocrinologist availability and out-of-pocket payment requirements restrict the penetration of advanced devices. Government outreach, such as tele-specialist nodes under eSanjeevani and state subsidies, is a critical lever. 

Regulatory Landscape

Diabetes devices in India are regulated by the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Medical Devices Rules (MDR), 2017. Oversight is led by the Drugs Controller General of India (DCGI). Under MDR, 2017, devices are risk-classified (Class A to Class D) and generally require licensing for manufacture and import through CDSCO processes, which determines the compliance pathway for glucose monitoring systems, insulin delivery devices, and key consumables.

For drug-device combinations, India does not run a standalone combination-product statute. Products containing both a drug and a device element are assessed as either a drug or a medical device based on the primary mode of action, and manufacturers can seek classification clarity from CDSCO. In April 2026, the Ministry of Health and Family Welfare issued draft Medical Devices (Amendment) Rules, 2026 for public comments, indicating active rulemaking under the MDR, 2017 framework that can affect technical documentation, labeling, and licensing expectations for diabetes-device manufacturers and importers.

Value Chain Analysis

The value chain covers upstream materials and components (sensor chips, enzymes and electrodes for monitoring systems, plastics and precision parts for pens and pumps, and primary packaging such as glass tubing for cartridges), then moves to device design, manufacturing or assembly, and quality and regulatory compliance under CDSCO. A recurring constraint is dependence on imported high-spec electronics and sensor inputs, which concentrates supply risk outside India even as domestic assembly grows. This has pushed companies toward localization where feasible, including Roche assembling Accu-Chek Active meters in Chennai and Schott commissioning borosilicate cartridge-tubing capacity in Gujarat in 2025 to reduce lead times for insulin-device components.

Downstream, hospitals and specialty clinics drive initial use for pumps and CGM starts, while retail and organized pharmacy channels support high-volume SMBG replenishment. E-pharmacy and digital-health platforms are also expanding through device-and-coaching bundles. Government manufacturing incentives, including the PLI program for medical devices, support local production economics, alongside an updated approved-applicant list released by the Department of Pharmaceuticals in November 2024. Still, affordability and infrastructure constraints, including patchy cold-chain capacity beyond metros, limit the reach of insulin cartridges and higher-end management devices in tier-2 and tier-3 markets.

Market Opportunities and Future Outlook

The strongest opportunity centers on reimbursement expansion combined with connected care. CGHS revised its 2024 rate list to raise ceilings to INR 300,000 for sensor-augmented pumps and INR 4,000 for 14-day CGM use, which provides clearer purchasing reference points for eligible beneficiaries and for provider systems. The public-sector digital backbone also creates room for device-plus-service models in home care. eSanjeevani surpassed 318.6 million cumulative consultations in 2024, and the Ayushman Bharat Digital Mission issued 568 million health IDs, supporting remote monitoring workflows and data sharing that can improve utilization of CGM, smart SMBG, and insulin-dose titration programs.

Local manufacturing depth remains a key lever for pricing and supply resilience, reinforced by the National Medical Devices Policy 2023 and the PLI program footprint. Developments in insulin-delivery ecosystems also point to investable demand for pens and cartridges: in July 2026, Shantha Biologics signed a manufacturing agreement with Novo Nordisk to perform cartridge fill-finish operations at its Hyderabad facility, and Shaily Engineering Plastics disclosed plans in May 2026 to scale GLP-1 pen capacity to over 150 million units by FY28. These moves align with the shift toward prefilled, patient-friendly delivery formats, supporting demand for compatible device components, sterile primary packaging, and India-focused distribution partnerships that can extend diabetes-device portfolios beyond metro specialist channels.